Cargando…

Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis

PURPOSE: Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a key role in hepatic fibrogenesis by virtue of its effect on the hepatic stellate cells (HSCs). Although many studies have shown that PPAR-γ agonists inhibit liver fibrosis, the mechanism remains largely unclear, especially rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Alatas, Fatima Safira, Matsuura, Toshiharu, Pudjiadi, Antonius Hocky, Wijaya, Stephanie, Taguchi, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354870/
https://www.ncbi.nlm.nih.gov/pubmed/32704495
http://dx.doi.org/10.5223/pghn.2020.23.4.346
_version_ 1783558182156632064
author Alatas, Fatima Safira
Matsuura, Toshiharu
Pudjiadi, Antonius Hocky
Wijaya, Stephanie
Taguchi, Tomoaki
author_facet Alatas, Fatima Safira
Matsuura, Toshiharu
Pudjiadi, Antonius Hocky
Wijaya, Stephanie
Taguchi, Tomoaki
author_sort Alatas, Fatima Safira
collection PubMed
description PURPOSE: Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a key role in hepatic fibrogenesis by virtue of its effect on the hepatic stellate cells (HSCs). Although many studies have shown that PPAR-γ agonists inhibit liver fibrosis, the mechanism remains largely unclear, especially regarding the cross-talk between PPAR-γ and other potent fibrogenic factors. METHODS: This experimental study involved 25 male Wistar rats. Twenty rats were subjected to bile duct ligation (BDL) to induce liver fibrosis, further divided into an untreated group (BDL; n=10) and a group treated with the PPAR-γ agonist thiazolidinedione (TZD), at 14 days post-operation (BDL+TZD; n=10). The remaining 5 rats had a sham operation (sham; n=5). The effect of PPAR-γ agonist on liver fibrosis was evaluated by histopathology, protein immunohistochemistry, and mRNA expression quantitative polymerase chain reaction. RESULTS: Histology and immunostaining showed markedly reduced collagen deposition, bile duct proliferation, and HSCs in the BDL+TZD group compared to those in the BDL group (p<0.001). Similarly, significantly lower mRNA expression of collagen α-1(I), matrix metalloproteinase-2, platelet-derived growth factor (PDGF)-B chain, and connective tissue growth factor (CTGF) were evident in the BDL+TZD group compared to those in the BDL group (p=0.0002, p<0.035, p<0.0001, and p=0.0123 respectively). Moreover, expression of the transforming growth factor beta1 (TGF-β1) was also downregulated in the BDL+TZD group (p=0.0087). CONCLUSION: The PPAR-γ agonist inhibits HSC activation in vivo and attenuates liver fibrosis through several fibrogenic pathways. Potent fibrogenic factors such as PDGF, CTGF, and TGF-β1 were downregulated by the PPAR-γ agonist. Targeting PPAR-γ activity may be a potential strategy to control liver fibrosis.
format Online
Article
Text
id pubmed-7354870
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition
record_format MEDLINE/PubMed
spelling pubmed-73548702020-07-22 Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis Alatas, Fatima Safira Matsuura, Toshiharu Pudjiadi, Antonius Hocky Wijaya, Stephanie Taguchi, Tomoaki Pediatr Gastroenterol Hepatol Nutr Original Article PURPOSE: Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a key role in hepatic fibrogenesis by virtue of its effect on the hepatic stellate cells (HSCs). Although many studies have shown that PPAR-γ agonists inhibit liver fibrosis, the mechanism remains largely unclear, especially regarding the cross-talk between PPAR-γ and other potent fibrogenic factors. METHODS: This experimental study involved 25 male Wistar rats. Twenty rats were subjected to bile duct ligation (BDL) to induce liver fibrosis, further divided into an untreated group (BDL; n=10) and a group treated with the PPAR-γ agonist thiazolidinedione (TZD), at 14 days post-operation (BDL+TZD; n=10). The remaining 5 rats had a sham operation (sham; n=5). The effect of PPAR-γ agonist on liver fibrosis was evaluated by histopathology, protein immunohistochemistry, and mRNA expression quantitative polymerase chain reaction. RESULTS: Histology and immunostaining showed markedly reduced collagen deposition, bile duct proliferation, and HSCs in the BDL+TZD group compared to those in the BDL group (p<0.001). Similarly, significantly lower mRNA expression of collagen α-1(I), matrix metalloproteinase-2, platelet-derived growth factor (PDGF)-B chain, and connective tissue growth factor (CTGF) were evident in the BDL+TZD group compared to those in the BDL group (p=0.0002, p<0.035, p<0.0001, and p=0.0123 respectively). Moreover, expression of the transforming growth factor beta1 (TGF-β1) was also downregulated in the BDL+TZD group (p=0.0087). CONCLUSION: The PPAR-γ agonist inhibits HSC activation in vivo and attenuates liver fibrosis through several fibrogenic pathways. Potent fibrogenic factors such as PDGF, CTGF, and TGF-β1 were downregulated by the PPAR-γ agonist. Targeting PPAR-γ activity may be a potential strategy to control liver fibrosis. The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020-07 2020-07-03 /pmc/articles/PMC7354870/ /pubmed/32704495 http://dx.doi.org/10.5223/pghn.2020.23.4.346 Text en Copyright © 2020 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition https://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Alatas, Fatima Safira
Matsuura, Toshiharu
Pudjiadi, Antonius Hocky
Wijaya, Stephanie
Taguchi, Tomoaki
Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
title Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
title_full Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
title_fullStr Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
title_full_unstemmed Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
title_short Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
title_sort peroxisome proliferator-activated receptor gamma agonist attenuates liver fibrosis by several fibrogenic pathways in an animal model of cholestatic fibrosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354870/
https://www.ncbi.nlm.nih.gov/pubmed/32704495
http://dx.doi.org/10.5223/pghn.2020.23.4.346
work_keys_str_mv AT alatasfatimasafira peroxisomeproliferatoractivatedreceptorgammaagonistattenuatesliverfibrosisbyseveralfibrogenicpathwaysinananimalmodelofcholestaticfibrosis
AT matsuuratoshiharu peroxisomeproliferatoractivatedreceptorgammaagonistattenuatesliverfibrosisbyseveralfibrogenicpathwaysinananimalmodelofcholestaticfibrosis
AT pudjiadiantoniushocky peroxisomeproliferatoractivatedreceptorgammaagonistattenuatesliverfibrosisbyseveralfibrogenicpathwaysinananimalmodelofcholestaticfibrosis
AT wijayastephanie peroxisomeproliferatoractivatedreceptorgammaagonistattenuatesliverfibrosisbyseveralfibrogenicpathwaysinananimalmodelofcholestaticfibrosis
AT taguchitomoaki peroxisomeproliferatoractivatedreceptorgammaagonistattenuatesliverfibrosisbyseveralfibrogenicpathwaysinananimalmodelofcholestaticfibrosis